Compare International Business Machines Corp (IBM) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
International Business Machines Corp vs Incyte Corporation — how do they compare? International Business Machines Corp trades at $234.19 (market cap $224.62B), while Incyte Corporation trades at $120.56 (market cap $24.54B). The key difference: International Business Machines Corp is far larger — about 9.2× Incyte Corporation's market cap, and International Business Machines Corp pays a 2.84% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| IBM | INCY | |
|---|---|---|
Market Cap | $224.62B | $24.54B |
Volume | 4,481,527 | — |
Sector | Technology | Health |
52-Week High | $329.23 | $129.93 |
52-Week Low | $205.77 | $81.61 |
Enterprise Value | $281.76B | $20.04B |
Dividend Yield | 2.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBM trades at $233.94, down 1.0% today, as the stock navigates mixed signals. Recent earnings showed a Q2 2026 EPS miss after two consecutive beats, while revenue growth accelerated to $67.54 billion in 2025. Technical indicators show a bullish overall signal but bearish moving averages, with RSI levels suggesting overbought conditions. The company secured a $240 million AI deal with Together AI, but faces securities fraud investigations following a 25% stock drop earlier this year.
IBM presents a complex risk-reward profile with strong profitability metrics (15.52% net margin, 34.62% ROE) and analyst consensus pointing to 10% upside to the $257.38 price target. However, ongoing legal investigations and increased capital expenditures creating negative cash flow pose significant near-term risks. The AI partnership momentum contrasts with concerns about IBM's competitive positioning in the rapidly evolving technology landscape.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
